ZCG-Backed Unimed Launches Medical Oxygen Solution, medO2 to Enhance Safety and Compliance for Vessels Worldwide

Integrated with Proprietary medScale+© Digital Platform for Continuous Monitoring of Critical Medical Supplies

NEW YORK--(BUSINESS WIRE)--Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, today announced the launch of medO2, an expanded range of maritime medical oxygen solutions designed to enhance safety and compliance for vessels around the world.

Onboard oxygen monitoring is often conducted manually, which can be inefficient and prone to errors. medO2 is a subscription-based oxygen service integrated into Unimed’s proprietary medScale+© digital platform, providing vessels with a streamlined way to manage and monitor both current and future onboard oxygen supplies. These supplies are essential for supporting urgent care and daily health needs for crew and passengers. Currently, over 6,500 vessels globally utilize the medScale+ platform through a mobile app or web browser, allowing Unimed’s medical team to remotely monitor, support, and deliver effective care to a growing customer base.

"Ensuring a sufficient supply of high-quality oxygen onboard is crucial for maritime crews, both for routine and emergency care,” said Søren Andersen, CEO of Unimed. “The addition of medO2 to Unimed’s subscription model will make it easier for maritime operators to maintain compliance with IMO and SOLAS medical oxygen requirements. Integrating this service with our medScale+ platform exemplifies our commitment to providing customers with greater efficiency through digital innovation. We are excited to reinforce Unimed’s position as the premier maritime medical partner, safeguarding health at sea for vessels globally."

“Unimed continues to drive the maritime industry forward with the next generation of technology-driven health solutions,” said James Zenni, Founder, President, and Chief Executive Officer of ZCG. “The launch of medO2, coupled with the increasing adoption of medScale+, enables Unimed to elevate the standard of care while scaling its business globally.”

For nearly 50 years, Unimed has been the trusted choice for maritime medical solutions, consistently evolving to meet the industry’s compliance and risk management needs. The medO2 expansion reflects Unimed’s ongoing commitment to digital and health innovations, ensuring maritime operators and their crew can navigate international waters with peace of mind.

About Unimed

Unimed is the industry leader in medical supply, equipment and oxygen distribution to global maritime industries, specializing in the delivery of integrated healthcare and safety supply chain logistical solutions to clients worldwide.

Unimed is a portfolio company of ZCG Private Equity, the private equity arm of ZCG (www.zcg.com), a leading privately held merchant bank comprised of private markets asset management, business consulting services, and technology development and solutions.

For more information, please visit https://universalmarinemedical.com/.

About ZCG

ZCG is a leading, privately held merchant bank comprised of three dynamic, cross-disciplinary platforms: private markets asset management, business consulting services, and technology development and solutions.

ZCG’s investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.

For almost 30 years, ZCG Principals have invested tens of billions of dollars of capital.

ZCG has a global team comprised of approximately 400 professionals. The company is headquartered in New York, with affiliate offices located in Pune and Mumbai, India, and Riyadh, KSA. For more information on ZCG, please visit www.zcg.com.